Literature DB >> 28392484

Use of CRISPR/Cas9 to model brain diseases.

Sen Yan1, Zhuchi Tu1, Shihua Li2, Xiao-Jiang Li3.   

Abstract

Aging-related brain diseases consist of a number of important neurodegenerative disorders, including Alzheimer's, Parkinson's, and Huntington's diseases, all of which have become more prevalent as the life expectancy of humans is prolonged. Age-dependent brain disorders are associated with both environmental insults and genetic mutations. For those brain disorders that are inherited, gene editing is an important tool for establishing animal models to investigate the pathogenesis of disease and identify effective treatments. Here we focus on the tools for gene editing, especially CRISPR/Cas9, and discuss their application for generating animal models that can recapitulate the brain pathology seen in human diseases. We also highlight the advantages and disadvantages of establishing genetically modified animal models. Finally, we discuss recent findings to resolve technical issues related to the use of CRISPR/Cas9 for generating animal models of brain diseases.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal models; CRISPR/Cas9; Gene editing; Neurodegeneration

Mesh:

Year:  2017        PMID: 28392484      PMCID: PMC5630495          DOI: 10.1016/j.pnpbp.2017.04.003

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  65 in total

1.  Systematic determination of the packaging limit of lentiviral vectors.

Authors:  M Kumar; B Keller; N Makalou; R E Sutton
Journal:  Hum Gene Ther       Date:  2001-10-10       Impact factor: 5.695

2.  Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system.

Authors:  Bernd Zetsche; Jonathan S Gootenberg; Omar O Abudayyeh; Ian M Slaymaker; Kira S Makarova; Patrick Essletzbichler; Sara E Volz; Julia Joung; John van der Oost; Aviv Regev; Eugene V Koonin; Feng Zhang
Journal:  Cell       Date:  2015-09-25       Impact factor: 41.582

Review 3.  The presenilins and Alzheimer's disease.

Authors:  M Hutton; J Hardy
Journal:  Hum Mol Genet       Date:  1997       Impact factor: 6.150

4.  Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells.

Authors:  Daesik Kim; Jungeun Kim; Junho K Hur; Kyung Wook Been; Sun-Heui Yoon; Jin-Soo Kim
Journal:  Nat Biotechnol       Date:  2016-06-06       Impact factor: 54.908

5.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

6.  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Manuela Neumann; Deepak M Sampathu; Linda K Kwong; Adam C Truax; Matthew C Micsenyi; Thomas T Chou; Jennifer Bruce; Theresa Schuck; Murray Grossman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Eliezer Masliah; Ian R Mackenzie; Howard Feldman; Wolfgang Feiden; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2006-10-06       Impact factor: 47.728

Review 7.  SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments.

Authors:  Peter I Joyce; Pietro Fratta; Elizabeth M C Fisher; Abraham Acevedo-Arozena
Journal:  Mamm Genome       Date:  2011-06-26       Impact factor: 2.957

8.  CRISPR/Cas9-mediated gene knock-down in post-mitotic neurons.

Authors:  Christoph Straub; Adam J Granger; Jessica L Saulnier; Bernardo L Sabatini
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

9.  Rapid modelling of cooperating genetic events in cancer through somatic genome editing.

Authors:  Francisco J Sánchez-Rivera; Thales Papagiannakopoulos; Rodrigo Romero; Tuomas Tammela; Matthew R Bauer; Arjun Bhutkar; Nikhil S Joshi; Lakshmipriya Subbaraj; Roderick T Bronson; Wen Xue; Tyler Jacks
Journal:  Nature       Date:  2014-10-22       Impact factor: 49.962

Review 10.  CRISPR/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases.

Authors:  Zhuchi Tu; Weili Yang; Sen Yan; Xiangyu Guo; Xiao-Jiang Li
Journal:  Mol Neurodegener       Date:  2015-08-04       Impact factor: 14.195

View more
  6 in total

Review 1.  White matter damage after traumatic brain injury: A role for damage associated molecular patterns.

Authors:  Molly Braun; Kumar Vaibhav; Nancy M Saad; Sumbul Fatima; John R Vender; Babak Baban; Md Nasrul Hoda; Krishnan M Dhandapani
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-05-19       Impact factor: 5.187

Review 2.  Basic and Preclinical Research for Personalized Medicine.

Authors:  Wanda Lattanzi; Cristian Ripoli; Viviana Greco; Marta Barba; Federica Iavarone; Angelo Minucci; Andrea Urbani; Claudio Grassi; Ornella Parolini
Journal:  J Pers Med       Date:  2021-04-29

Review 3.  Genome-editing applications of CRISPR-Cas9 to promote in vitro studies of Alzheimer's disease.

Authors:  Vo Van Giau; Hyon Lee; Kyu Hwan Shim; Eva Bagyinszky; Seong Soo A An
Journal:  Clin Interv Aging       Date:  2018-02-07       Impact factor: 4.458

4.  The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Alzheimer's Disease.

Authors:  Troy T Rohn; Nayoung Kim; Noail F Isho; Jacob M Mack
Journal:  J Alzheimers Dis Parkinsonism       Date:  2018-05-31

Review 5.  Applications of CRISPR-Cas9 in Alzheimer's Disease and Related Disorders.

Authors:  Laura M De Plano; Giovanna Calabrese; Sabrina Conoci; Salvatore P P Guglielmino; Salvatore Oddo; Antonella Caccamo
Journal:  Int J Mol Sci       Date:  2022-08-05       Impact factor: 6.208

Review 6.  Multifunctional Polymeric Nanoplatforms for Brain Diseases Diagnosis, Therapy and Theranostics.

Authors:  Shahryar Shakeri; Milad Ashrafizadeh; Ali Zarrabi; Rasoul Roghanian; Elham Ghasemipour Afshar; Abbas Pardakhty; Reza Mohammadinejad; Anuj Kumar; Vijay Kumar Thakur
Journal:  Biomedicines       Date:  2020-01-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.